Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1688453 | 0.83 | SIGMAR1 (0.31) | — | |
| SCHEMBL1288487 | 0.76 | ATR (0.37) | ADRB2LOXL2 | |
| SCHEMBL2608751 | 0.74 | CYP2C19 (0.36) | — | |
| SCHEMBL27167015 | 0.74 | F2RL1 (0.35) | — | |
| SCHEMBL14726427 | 0.73 | ADRB2 (0.37) | ADRB2LOXL2 | |
| SCHEMBL26103015 | 0.73 | DGAT1 (0.36) | — | |
| SCHEMBL14895808 | 0.71 | ALOX5AP (0.37) | — | |
| SCHEMBL2608767 | 0.70 | CHRM2 (0.41) | — | |
| SCHEMBL2598302 | 0.69 | DGAT1 (0.32) | — | |
| SCHEMBL31104413 | 0.69 | HTT (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150126502-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARM INC (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126502-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARM INC (US) | 2015-05-07 | — | — | US | disclosed |
| EP-2516441-B1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | ELAN PHARM INC (US) | 2015-01-21 | — | — | EP | disclosed |
| EP-2516441-B1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | ELAN PHARM INC (US) | 2015-01-21 | — | — | EP | disclosed |
| US-20130331376-A1 | INHIBITORS OF POLO-LIKE KINASE | Elan Corporation, Inc. (US) | 2013-12-12 | — | — | US | disclosed |
| EP-2661268-A2 | INHIBITORS OF POLO-LIKE KINASE | Elan Pharmaceuticals Inc. (US) | 2013-11-13 | — | — | EP | disclosed |
| US-8541418-B2 | Inhibitors of polo-like kinase | ELAN PHARMACEUTICAL, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541418-B2 | Inhibitors of polo-like kinase | ELAN PHARMACEUTICAL, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541418-B2 | Inhibitors of polo-like kinase | ELAN PHARMACEUTICAL, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20130231335-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20110212942-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
| US-20110212942-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
| US-20110212942-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
| US-20110207716-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-08-25 | — | — | US | disclosed |
| US-20110207716-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-08-25 | — | — | US | disclosed |
| US-20110207716-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-08-25 | — | — | US | disclosed |
| WO-2011079118-A1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC (US) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079114-A1 | PTERIDINONES AS INHIBITORS OF POLO - LIKE KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079118-A1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC (US) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079114-A1 | PTERIDINONES AS INHIBITORS OF POLO - LIKE KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212942-A1 | INHIBITORS OF POLO-LIKE KINASE | PLK1, POLK, POLR2E | ADRB2 3564/4885LOXL2 2334/4885 |
| US-20130331376-A1 | INHIBITORS OF POLO-LIKE KINASE | PLK1, POLK, POLR2E | ADRB2 3281/4885LOXL2 2439/4885 |
| US-20130231335-A1 | INHIBITORS OF POLO-LIKE KINASE | POLK, PLK1, POLR2E | ADRB2 3624/4885LOXL2 2404/4885 |
| US-20110207716-A1 | INHIBITORS OF POLO-LIKE KINASE | PLK1, POLK, POLR2E | ADRB2 3281/4885LOXL2 2439/4885 |
| US-20150126502-A1 | INHIBITORS OF POLO-LIKE KINASE | POLK, PLK1, POLR2E | ADRB2 3624/4885LOXL2 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.